133099-09-9 Usage
Description
(S)-3-(1-Cyano-1,1-diphenylmethyl)-1-tosylpyrrolidine, also known as (3S)-1-Tosyl-α,α-diphenyl-3-pyrrolidineacetonitrile, is a chiral compound with a unique molecular structure. It consists of a pyrrolidine ring with a tosyl group at the 1-position, a cyano group at the 3-position, and two phenyl groups attached to the carbon adjacent to the cyano group. (S)-3-(1-Cyano-1,1-diphenylmethyl)-1-tosylpyrrolidine is an important intermediate in the synthesis of various pharmaceuticals and organic compounds.
Uses
Used in Pharmaceutical Industry:
(S)-3-(1-Cyano-1,1-diphenylmethyl)-1-tosylpyrrolidine is used as a key reactant in the preparation of Darifenacin Hydrobromide (D193400), a medication used to treat urinary incontinence. Darifenacin Hydrobromide works by selectively blocking the M3 muscarinic acetylcholine receptor, which helps to control involuntary muscle contractions in the bladder.
In the synthesis of Darifenacin Hydrobromide, (S)-3-(1-Cyano-1,1-diphenylmethyl)-1-tosylpyrrolidine serves as a crucial building block, providing the necessary chiral center and structural features required for the final product. (S)-3-(1-Cyano-1,1-diphenylmethyl)-1-tosylpyrrolidine's unique properties and reactivity make it an essential component in the development of this medication, contributing to its effectiveness in managing urinary incontinence.
Check Digit Verification of cas no
The CAS Registry Mumber 133099-09-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,3,0,9 and 9 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 133099-09:
(8*1)+(7*3)+(6*3)+(5*0)+(4*9)+(3*9)+(2*0)+(1*9)=119
119 % 10 = 9
So 133099-09-9 is a valid CAS Registry Number.
InChI:InChI=1/C25H24N2O2S/c1-20-12-14-24(15-13-20)30(28,29)27-17-16-23(18-27)25(19-26,21-8-4-2-5-9-21)22-10-6-3-7-11-22/h2-15,23H,16-18H2,1H3/t23-/m1/s1
133099-09-9Relevant articles and documents
IMPROVED PROCESS FOR PRODUCING DARIFENACIN
-
, (2009/11/29)
The present invention discloses an improved process for producing darifenacin, the process comprising decarboxylating (2S,4R)-4-hydroxy-2-pyrrolidine carboxylic acid followed by in situ tosylation to give l-tosyl-3-(R)-(-)-hydroxypyrrolidine, tosylating the l-tosyl-3-(R)-(-)-hydroxypyrrolidine with methyl-p-toluenesuolphonate to give l-tosyl-3- (S)-(-)-tosyloxy pyrrolidine, reacting l-tosyl-3-(S)-(-)-tosyloxy pyrrolidine with diphenyl acetonitrile in presence of a base to give 3-(S)-(+)-(l-cyano-l,l-diphenylmethyl)-l- tosylpyrrolidine, de-protecting 3-(S)-(+)-(l-cyano-l,l-diphenylmethyl)-l- tosylpyrrolidine in the presence of phenol in acidic medium to give 3-(S)-(+)-(l-cyano- 1,1-diphenylmethyl) pyrrolidine, hydrolyzing 3-(S)-(+)-(l-cyano-l,l-diphenylmethyl) pyrrolidine followed by salt formation to obtain 3-(S)-(+)-(l-carbamoyl-l,l- diphenylmethyl)pyrrolidine.L-(+)-tartrate, condensing 3-(S)-(+)-( 1 -carbamoyl- 1,1- diphenylmethyl)pyrrolidine-L(+)-tartrate with 5-(2-bromoethyl)-2,3-dihydrobenzofuran employing a base in a solvent to give darifenacin.
NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF INTERMEDIATES OF DARIFENACIN, DARIFENACIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
-
, (2008/12/08)
The present invention relates to novel and improved processes for the preparation of intermediates of darifenacin, darifenacin and its pharmaceutically acceptable salts. Darifenacin is chemically known as 3 -(S)-(-)-(l -carbamoyl- 1,1 -diphenylmethyl)-l- [2- (2,3-dihydro benzofuran-5-yl)ethyl]pyrrolidine and represented by formula-2. The invention also relates to the novel polymorphs of the pharmaceutically acceptable salts of darifenacin and the methods for their re aration.
PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE
-
Page/Page column 39, (2008/06/13)
The invention encompasses processes for the preparation of darifenacin hydrobromide.
